PDF(Pubmed)
Abstract：
OBJECTIVE: The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface.
RESULTS: Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.
RESULTS: Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.
摘要：
目的：这篇综述的目的，将介绍SAC和PAC主题管理的最新修订版，基于现有的科学证据，并专注于眼用溶液配方对眼表面的影响。
结果：治疗眼部过敏的医生应注意SAC和PAC的泪膜和泪膜破坏，以及眼药水成分和添加剂如何影响过敏眼的生理。季节性和常年性过敏性结膜炎（SAC和PAC）是眼过敏（OA）的最常见原因，这两种情况都未得到诊断和治疗。SAC和PAC是免疫球蛋白E(IgE)介导的超敏反应。由炎性介质的释放引起的额外的泪膜破坏增加并加剧体征和症状的影响,并且可能引发眼表的损伤。合并症很常见,特别是干眼症必须考虑。SAC和PAC治疗的临床指南推荐抗组胺药的局部治疗。肥大细胞稳定剂或双作用剂作为一线治疗，但是应该小心，因为许多药物含有其他可能导致眼表损伤的化合物。
结果：治疗眼部过敏的医生应注意SAC和PAC的泪膜和泪膜破坏，以及眼药水成分和添加剂如何影响过敏眼的生理。季节性和常年性过敏性结膜炎（SAC和PAC）是眼过敏（OA）的最常见原因，这两种情况都未得到诊断和治疗。SAC和PAC是免疫球蛋白E(IgE)介导的超敏反应。由炎性介质的释放引起的额外的泪膜破坏增加并加剧体征和症状的影响,并且可能引发眼表的损伤。合并症很常见,特别是干眼症必须考虑。SAC和PAC治疗的临床指南推荐抗组胺药的局部治疗。肥大细胞稳定剂或双作用剂作为一线治疗，但是应该小心，因为许多药物含有其他可能导致眼表损伤的化合物。
